Ratings
0
Nobody has rated this yet. Be the first!
Works
4
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party
Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms
Dose intensification with autologous stem cell transplantation in relapsed and resistant Hodgkin's disease.
Response of prostate cancer during imatinib therapy in a patient with chronic myeloid leukemia.
